Blueprint Medicines logoBlueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

Blueprint Medicines announced today that the FDA and the EMA have accepted their NDA (new drug application) for approval for avapritinib. This does not mean the drug is approved but has been accepted for review as a next step in the approval process.

http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-acceptance-new-drug

Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST

http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-european-medicines-agency